Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

Hepatol Int. 2024 Apr;18(2):702-703. doi: 10.1007/s12072-024-10642-0. Epub 2024 Mar 2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenine / adverse effects
  • Dyslipidemias* / chemically induced
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Tenofovir / adverse effects

Substances

  • Adenine
  • Tenofovir